Mereo BioPharma MREO Stock
Mereo BioPharma Price Chart
Mereo BioPharma MREO Financial and Trading Overview
Mereo BioPharma stock price | 2.21 USD |
Previous Close | 1.38 USD |
Open | 1.38 USD |
Bid | 0 USD x 1800 |
Ask | 0 USD x 1400 |
Day's Range | 1.37 - 1.52 USD |
52 Week Range | 0.5 - 1.85 USD |
Volume | 3.03M USD |
Avg. Volume | 2.01M USD |
Market Cap | 178.73M USD |
Beta (5Y Monthly) | 0.838849 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.06 USD |
MREO Valuation Measures
Enterprise Value | 128.58M USD |
Trailing P/E | N/A |
Forward P/E | -0.0275 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.8830645 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -2.961 |
Trading Information
Mereo BioPharma Stock Price History
Beta (5Y Monthly) | 0.838849 |
52-Week Change | 10.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.85 USD |
52 Week Low | 0.5 USD |
50-Day Moving Average | 1.15 USD |
200-Day Moving Average | 0.95 USD |
MREO Share Statistics
Avg. Volume (3 month) | 2.01M USD |
Avg. Daily Volume (10-Days) | 3.85M USD |
Shares Outstanding | 124.99M |
Float | 79.28M |
Short Ratio | 3.81 |
% Held by Insiders | 0% |
% Held by Institutions | 51.67% |
Shares Short | 8.25M |
Short % of Float | N/A |
Short % of Shares Outstanding | 6.60% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -25.39% |
Return on Equity (ttm) | -45.63% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 936K USD |
EBITDA | -43425000 USD |
Net Income Avi to Common (ttm) | -34196000 USD |
Diluted EPS (ttm) | -0.42 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 56.33M USD |
Total Cash Per Share (mrq) | 0.45 USD |
Total Debt (mrq) | 12.77M USD |
Total Debt/Equity (mrq) | 20.65 USD |
Current Ratio (mrq) | 2.518 |
Book Value Per Share (mrq) | 0.496 |
Cash Flow Statement
Operating Cash Flow (ttm) | -38820000 USD |
Levered Free Cash Flow (ttm) | -22523750 USD |
Profile of Mereo BioPharma
Country | United States |
State | N/A |
City | London |
Address | One Cavendish Place |
ZIP | W1G 0QF |
Phone | 44 33 3023 7300 |
Website | https://www.mereobiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 36 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Q&A For Mereo BioPharma Stock
What is a current MREO stock price?
Mereo BioPharma MREO stock price today per share is 2.21 USD.
How to purchase Mereo BioPharma stock?
You can buy MREO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mereo BioPharma?
The stock symbol or ticker of Mereo BioPharma is MREO.
Which industry does the Mereo BioPharma company belong to?
The Mereo BioPharma industry is Biotechnology.
How many shares does Mereo BioPharma have in circulation?
The max supply of Mereo BioPharma shares is 159M.
What is Mereo BioPharma Price to Earnings Ratio (PE Ratio)?
Mereo BioPharma PE Ratio is now.
What was Mereo BioPharma earnings per share over the trailing 12 months (TTM)?
Mereo BioPharma EPS is -0.3 USD over the trailing 12 months.
Which sector does the Mereo BioPharma company belong to?
The Mereo BioPharma sector is Healthcare.
Mereo BioPharma MREO included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}